Navigation Links
Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
Date:1/6/2011

SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.  Allopurinol currently accounts for greater than 90% of the unit sales of chronic gout prescription medications; however, in controlled trials, only 30-40% of gout patients respond adequately to allopurinol as defined by the achievement of a serum uric acid (sUA) level of less than 6 mg/dL, the medically recommended target.  In this Phase 2b study, the primary and key secondary endpoints were achieved, with highly statistically significant reductions in sUA and up to 89% of patients taking a combination of RDEA594 600 mg and allopurinol reaching target sUA.  RDEA594, Ardea's lead product candidate for the chronic treatment of gout, is an orally administered compound that inhibits the URAT1 transporter, a biological mechanism that is complementary to the mechanism of allopurinol and that of the most recently approved oral drug for gout, febuxostat (Uloric ®).

This was a 28-day, randomized, double-blind, placebo-controlled, study conducted in 208 gout patients with elevated uric acid levels (sUA greater than or equal to 6 mg/dL) despite being on a stable dose of allopurinol.  In the study, patients remained on a stable dose of allopurinol and also received once daily doses of 200 mg RDEA594, 400 mg RDEA594, 600 mg RDEA594 or placebo.  For patients randomized to receive 400 mg RDEA594 and 600 mg RDEA594, the RDEA594 daily dose was escalated weekly in increments of 200 mg/day.  The primary endpoint of the study was the percent reduction in sUA after 4 weeks of treatment with the combination compared to allopurinol alone.  A key secondary efficacy endpoint was the proportion of patients
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Ardea Biosciences to Present at Two Upcoming Investor Conferences
2. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
3. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
4. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
7. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
8. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
9. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... A recent study from researchers in Tasmania ... that those who took probiotics were able to run for ... showed that in extreme heat conditions, probiotics were able to ... acne treatment explains what this new discovery means for ... skin condition. , While researchers tote the benefits of ...
(Date:5/21/2013)... 2013 First patients dosed with ... bromide designed using Prosonix, particle engineering platform ... of inhaled Respiratory Medicines by Design , has ... will assess its effect on lung function and the ... moderate to severe chronic obstructive pulmonary disease (COPD). The ...
(Date:5/21/2013)... May 21, 2013 Custom Learning ... reporting eLearning solution using Tin Can API combined ... tool. CLD is a leading developer of training ... device companies worldwide. , Tin Can API ... helps learners and trainers more accurately measure the ...
(Date:5/21/2013)... 2013 Alpha Source, Inc., a ... be exhibiting for the 13th consecutive year at ... (AAMI) 2013 Conference and Expo. The conference brings ... manufacture healthcare technologies. This year’s event will be ... , The three-day event draws over 1,500 ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2
... ... ... 2009 -- iSirona®, an innovative provider of data automation solutions for healthcare providers, today announced ... replaces Chairman Dave Dyell, iSirona,s founder, who will continue to serve as the company,s CEO ...
... , NEW YORK, Nov. 9 "Micro cap and small cap ... and exposure as a ,buying window, opens and to take advantage ... metals," states Herbert Haft, President of The Haft Group, Inc, Manhattan ... and small cap equities market in the US and Canada, and ...
... SHANGHAI, Nov. 9 /PRNewswire-Asia/ -- The pharma and ... The companies are facing significant,pressure to change with ... a greater regulatory burden, these conditions together with,the financial ... harder than ever.,Big pharmaceutical companies are being forced to ...
Cached Biology Technology:iSirona Selects New Chairman of the Board 2Haft Group says Bullish Commodity Market Triggers Small and Micro-cap Upsurge 2Pharma and Biotech Leaders to Converge in Shanghai 2
(Date:5/22/2013)... environmental and human health effects from disposal of ... led scientists to recommend stronger government policies to ... battery materials. That,s the conclusion of a new ... & Technology . , Oladele A. Ogunseitan and ... mainstays for powering everything from smart phones to ...
(Date:5/22/2013)... feared Legionella pneumophila bacteria is responsible for ... In order to infect us, this pathogen has developed ... go unnoticed in our cells, thus avoiding these acting ... Basque biosciences research centre, CIC bioGUNE, in which teams ... USA and the National Supercomputation Centre in Barcelona (BSC) ...
(Date:5/22/2013)... 2013 Early screening for prostate cancer could become ... for women, thanks to UC Irvine research published today ... . , After more than a decade of work, ... identify clinically usable markers for prostate cancer in urine, ... with greater accuracy and at dramatically lower cost. The ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... the excitement of Census of Marine Life explorations as ... surface of the global ocean. A world of marine ... colossal sea star, and Antarctica,s biggest-ever amphipod and other ... at http://earth.google.com/ocean . Or one can follow along ...
... Edible fungus foils dangerous grapefruit-drug interactions, Journal ... Florida report that adding an edible mushroom-like fungus to ... effects that can occur when people taking certain prescription ... January 14 edition of the ACS, bi-weekly Journal ...
... by Duke University bioengineers can help clinicians more precisely ... give basic researchers a powerful new tool to better ... interpreting how beams of light scatter off of tumor ... responding to chemotherapeutic agents within a matter of hours. ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Jan. 28, 2009 2American Chemical Society's Weekly PressPac -- Jan. 28, 2009 3American Chemical Society's Weekly PressPac -- Jan. 28, 2009 4American Chemical Society's Weekly PressPac -- Jan. 28, 2009 5American Chemical Society's Weekly PressPac -- Jan. 28, 2009 6Scattered light rapidly detects tumor response to chemotherapy 2Scattered light rapidly detects tumor response to chemotherapy 3
... [E12] to MAP1 Light Chain MAP1A and ... interactions between microtubules and components of the cytoskeleton. ... chain subunit and multiple light chain subunits. The ... the light chain subunits and can associate with ...
... as smooth muscle cell specific protein, is reported ... tissues such as intestine, lung and uterus. It ... SM22 alpha expression has been reported in most ... and visceral forms. It is also reported to ...
... ChromaDoc-It features a 4.1 mega pixel ... capturing brilliant TLC color images., The ... shortwave and longwave UV tubes positioned on ... illumination for fluorescence studies , Interior ...
Pendrin (H-195)...
Biology Products: